Wednesday, October 28, 2026
11:00 AM – 12:00 PM ET
Cancer immunotherapies leverage the body’s immune system to detect and destroy malignant cells, yet tumor heterogeneity can affect how patients respond and eventually develop resistance. Recent advances in molecular biology are revealing ever‑finer details of the tumor microenvironment, tumor‑specific antigens, and the intricate crosstalk between immune cells, opening new avenues to decode the mechanisms that drive treatment success or failure.
In this research roundtable, leading experts will explore the latest directions in cancer immunotherapy, covering topics from comprehensive profiling of the tumor microenvironment and identification of neoantigens to the design of novel cell‑based therapies. The panelists will also dissect common hurdles in preclinical immunotherapy studies and discuss how molecular discoveries can shape the creation and assessment of next‑generation therapeutic approaches.
Attendees will
- Learn how molecular profiling uncovers mechanisms driving response and resistance to cancer immunotherapies.
- Examine methods for characterizing the tumor microenvironment and pinpointing neoantigens with therapeutic potential.
- Discuss emerging strategies and key research considerations for cell‑therapy development.
- Outline major challenges in preclinical immunotherapy research and highlight opportunities to improve translational success.
William Williams, MD
President and CEO, BriaCell Therapeutics Corp.
Also Read
- The Moral Argument for Human Embryo Gene Editing: A Biotech Founder’s Perspective
- Intricate Neural Waves Shed Light on the Brain’s Dynamic Processing
- Cannabis Use Linked to Higher Risks of Committing and Experiencing Violence, Large Review Finds
- Cloudflare plans to issue quantum-safe TLS certificates